



NEWS RELEASE

Bruker Corporation to Present at Investor Conferences

5/7/2021

BILLERICA, Mass.--(BUSINESS WIRE)-- **Bruker Corporation** (Nasdaq: BRKR) announced today it will participate in the following virtual conferences:

BofA Securities 2021 Health Care Conference

Tuesday, May 11, 2021, at 11:00 a.m. Eastern Time

Frank Laukien, Chairman, President and Chief Executive Officer

Mark Munch, President, Bruker Nano Group

UBS Global Healthcare Virtual Conference

Monday, May 24, 2021, at 9:00 a.m. Eastern Time

Frank Laukien, Chairman, President and Chief Executive Officer

Mark Munch, President, Bruker Nano Group

Jefferies Virtual Healthcare Conference

Wednesday, June 2, 2021, at 8:00 a.m. Eastern Time

Frank Laukien, Chairman, President and Chief Executive Officer

Juergen Srega, President, Bruker CALID Group

Live audio webcasts of the virtual presentation and “fireside” sessions will be available on the Investor Relations section of the Company's website at <https://ir.bruker.com>. Replays will be posted on Bruker's Investor Relations website after each event and will be available for 30 days following the presentation.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210507005145/en/): <https://www.businesswire.com/news/home/20210507005145/en/>

Miroslava Minkova

Senior Director, Investor Relations & Corporate Development

Bruker Corporation

T: +1 (978) 663 - 3660, ext. 1479

E: Investor.Reations@bruker.com

Source: Bruker Corporation